Logo do repositório
 
Publicação

Biomimetic bright optotheranostics for metastasis monitoring and multimodal image-guided breast cancer therapeutics

2024-03Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorPrasad, Rajendra
dc.contributor.authorPeng, Berney
dc.contributor.authorMendes, Bárbara B.
dc.contributor.authorKilian, Hailey I.
dc.contributor.authorGorain, Mahadeo
dc.contributor.authorZhang, Huijuan
dc.contributor.authorKundu, Gopal Chandra
dc.contributor.authorXia, Jun
dc.contributor.authorLovell, Jonathan F.
dc.contributor.authorConde, João
dc.contributor.authorConde, João
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.institutionCentre for Toxicogenomics and Human Health (ToxOmics)
dc.contributor.pblElsevier
dc.date.accessioned2024-02-16T01:10:25Z
dc.date.available2024-02-16T01:10:25Z
dc.date.issued2024-03
dc.descriptionFunding Information: R.P. would like to thank the Director and the School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi for the support during preparation of this manuscript. R.P. also thanks the support of Tufts University , J.C. and B.B.M. acknowledge the European Research Council (Grant Agreement 848325 ). B.B.M., H.I.K., H.Z. and M.G. contributed equally to this project. We thank Dr. Gupta for critical reading of the manuscript and discussions on tumor imaging and therapeutic data. M.G. and G.C.K. thank support from NCCS , Pune and KIIT . H.I.K., H.Z., J.X. and J.F.L would like to thank the support from the University at Buffalo . Funding Information: J.C. is a co-founder and shareholder of TargTex S.A – Targeted Therapeutics for Glioblastoma Multiforme. J.C. is a member of the Global Burden Disease (GBD) consortium from Institute for Health Metrics and Evaluation (IHME), University of Washington (US). All the other authors declare no conflict of interest.R.P. would like to thank the Director and the School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi for the support during preparation of this manuscript. R.P. also thanks the support of Tufts University, J.C. and B.B.M. acknowledge the European Research Council (Grant Agreement 848325). B.B.M. H.I.K. H.Z. and M.G. contributed equally to this project. We thank Dr. Gupta for critical reading of the manuscript and discussions on tumor imaging and therapeutic data. M.G. and G.C.K. thank support from NCCS, Pune and KIIT. H.I.K. H.Z. J.X. and J.F.L would like to thank the support from the University at Buffalo. Publisher Copyright: © 2024 The Author(s)
dc.description.abstractNanoparticle formulations blending optical imaging contrast agents and therapeutics have been a cornerstone of preclinical theranostic applications. However, nanoparticle-based theranostics clinical translation faces challenges on reproducibility, brightness, photostability, biocompatibility, and selective tumor targeting and penetration. In this study, we integrate multimodal imaging and therapeutics within cancer cell-derived nanovesicles, leading to biomimetic bright optotheranostics for monitoring cancer metastasis. Upon NIR light irradiation, the engineered optotheranostics enables deep visualization and precise localization of metastatic lung, liver, and solid breast tumors along with solid tumor ablation. Metastatic cell-derived nanovesicles (∼80 ± 5 nm) are engineered to encapsulate imaging (emissive organic dye and gold nanoparticles) and therapeutic agents (anticancer drug doxorubicin and photothermally active organic indocyanine green dye). Systemic administration of biomimetic bright optotheranostic nanoparticles shows escape from mononuclear phagocytic clearance with (i) rapid tumor accumulation (3 h) and retention (up to 168 h), (ii) real-time monitoring of metastatic lung, liver, and solid breast tumors and (iii) 3-fold image-guided solid tumor reduction. These findings are supported by an improvement of X-ray, fluorescence, and photoacoustic signals while demonstrating a tumor reduction (201 mm3) in comparison with single therapies that includes chemotherapy (134 mm3), photodynamic therapy (72 mm3), and photothermal therapy (88 mm3). The proposed innovative platform opens new avenues to improve cancer diagnosis and treatment outcomes by allowing the monitorization of cancer metastasis, allowing the precise cancer imaging, and delivering synergistic therapeutic agents at the solid tumor site.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent16
dc.format.extent17721192
dc.identifier.doi10.1016/j.jconrel.2024.01.056
dc.identifier.issn0168-3659
dc.identifier.otherPURE: 82799718
dc.identifier.otherPURE UUID: 20b82b12-de8f-4bd0-a818-b1320836d04e
dc.identifier.otherScopus: 85183586843
dc.identifier.otherPubMed: 38281670
dc.identifier.urihttp://hdl.handle.net/10362/163604
dc.identifier.urlhttps://www.scopus.com/pages/publications/85183586843
dc.language.isoeng
dc.peerreviewedyes
dc.subjectBiomimetic
dc.subjectBright optotheranostics
dc.subjectMetastasis
dc.subjectMultimodal imaging and therapy
dc.subjectSolid tumor
dc.subjectPharmaceutical Science
dc.subjectSDG 3 - Good Health and Well-being
dc.titleBiomimetic bright optotheranostics for metastasis monitoring and multimodal image-guided breast cancer therapeuticsen
dc.typejournal article
degois.publication.firstPage300
degois.publication.lastPage315
degois.publication.titleJournal of Controlled Release
degois.publication.volume367
dspace.entity.typePublication
person.familyNameConde
person.givenNameJoão
person.identifier807432
person.identifier.ciencia-idA71C-B10E-255E
person.identifier.orcid0000-0001-8422-6792
person.identifier.ridF-2231-2011
person.identifier.scopus-author-id56992468300
rcaap.rightsopenAccess
relation.isAuthorOfPublication33ca4178-1b25-4b5e-ae16-b2500abe4c58
relation.isAuthorOfPublication.latestForDiscovery33ca4178-1b25-4b5e-ae16-b2500abe4c58

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
1-s2.0-S0168365924000713-main.pdf
Tamanho:
16.9 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica